New cancer pill enters human testing for Tough-to-Treat tumors

This is the first human study of an experimental oral medication called ODM-212 for people with advanced solid tumors that have stopped responding to standard treatments. The trial will test the drug's safety, determine the right dose, and see if it shows any anti-cancer activity in 315 adults with specific tumor types like mesothelioma, lung cancer, and others. Researchers are particularly interested in tumors with certain genetic changes in what's called the Hippo pathway.